Description: <p><b>Celastrol</b> — a quinone methide pentacyclic triterpenoid natural product isolated mainly from <i>Tripterygium wilfordii</i> and related Celastraceae plants. It is best classified as a pleiotropic redox-reactive small molecule with proteostasis-disrupting, anti-inflammatory, and anticancer activity. Standard abbreviations include Cel and CeT. In oncology, celastrol is best viewed as a preclinical multi-target stress inducer rather than a selective single-node inhibitor, with recurring emphasis on thiol-reactive proteostasis disruption, NF-κB suppression, ROS-linked mitochondrial injury, and context-dependent inhibition of STAT3 and PI3K/AKT signaling. Clinically important caveats are poor water solubility, poor oral bioavailability, rapid disposition, and a narrow therapeutic window that has driven strong interest in nanoformulations and conjugates.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Proteostasis disruption with functional HSP90 inhibition and heat-shock response activation</li>
<li>NF-κB pathway suppression through inhibition of pro-survival inflammatory signaling</li>
<li>ROS elevation with mitochondrial dysfunction and intrinsic apoptosis</li>
<li>JAK2/STAT3 axis inhibition in responsive tumor contexts</li>
<li>Secondary down-modulation of PI3K/AKT/mTOR and related growth-survival signaling</li>
<li>Context-dependent suppression of invasion, angiogenesis, and metastatic programs including CXCR4 and HIF-1-related outputs</li>
<li>Chemosensitization and stress-vulnerability amplification in selected resistant tumor models</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Celastrol is practically insoluble or very poorly soluble in water, has poor oral bioavailability, and shows dose-limiting systemic toxicity; delivery systems are commonly used to improve exposure and reduce off-target injury.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Many mechanistic and cytotoxicity studies use low-micromolar concentrations that are difficult to reproduce safely with conventional systemic dosing. Some pathway effects may still occur at lower exposures, but direct tumoricidal effects are often concentration-limited without advanced formulations.</p>
<p><b>Clinical evidence status:</b> Strong preclinical oncology signal; early translational and formulation work; no approved cancer indication. Human clinical registration appears limited to non-oncology safety/other exploratory studies rather than established anticancer efficacy trials. *** Appears more useful used at lower doses in combined treatment approaches.</p>
<b>Celastrol</b>—a bioactive compound extracted from traditional Chinese medicinal plants such as Tripterygium wilfordii (Thunder God Vine).<br>
<br>
Pathways:<br>
-inhibit NF-κB activation<br>
-disrupt the function of chaperone proteins like HSP90 and HSP70, which are often overexpressed in cancer cells<br>
-attenuate Akt phosphorylation and downstream mTOR signaling<br>
-modulate components of the MAPK pathway, including ERK, JNK, and p38.<br>
-increase intracellular ROS levels in cancer cells<br>
-inhibiting STAT3<br>
<h3>Celastrol mechanistic map in cancer</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>HSP90 proteostasis disruption</td>
<td>↓ client protein stability; ↑ heat-shock stress</td>
<td>↑ stress response (dose-dependent)</td>
<td>P/R</td>
<td>Destabilization of oncogenic signaling networks</td>
<td>Mechanistically central and industry-relevant. Celastrol behaves as a thiol-reactive disruptor of chaperone-dependent proteostasis rather than a highly selective kinase inhibitor.</td>
</tr>
<tr>
<td>2</td>
<td>NF-κB inflammatory survival signaling</td>
<td>↓</td>
<td>↓ inflammatory tone</td>
<td>R/G</td>
<td>Reduced survival, proliferation, cytokine signaling, and invasion</td>
<td>One of the most reproducible anticancer themes; also helps explain anti-inflammatory overlap outside oncology.</td>
</tr>
<tr>
<td>3</td>
<td>Mitochondrial ROS increase</td>
<td>↑ (primary; dose-dependent)</td>
<td>↑ (high concentration only)</td>
<td>P/R</td>
<td>Oxidative stress overload and stress sensitization</td>
<td>The quinone methide scaffold is redox-reactive. ROS often acts upstream of mitochondrial depolarization, apoptosis, and therapy sensitization.</td>
</tr>
<tr>
<td>4</td>
<td>Mitochondria and intrinsic apoptosis</td>
<td>MMP ↓; Bax/Bcl-2 balance toward apoptosis; caspases ↑</td>
<td>↑ injury at higher exposure</td>
<td>R/G</td>
<td>Apoptotic tumor cell death</td>
<td>Usually linked to ROS and proteotoxic stress rather than an isolated primary target.</td>
</tr>
<tr>
<td>5</td>
<td>JAK2 STAT3 signaling</td>
<td>↓ (context-dependent)</td>
<td>↔</td>
<td>R/G</td>
<td>Reduced proliferation, survival, and inflammatory transcription</td>
<td>Supported in multiple tumor models, including myeloma and more recent metastatic-cancer work, but not necessarily dominant in every model.</td>
</tr>
<tr>
<td>6</td>
<td>PI3K AKT mTOR axis</td>
<td>↓ (secondary)</td>
<td>↔ / ↓</td>
<td>R/G</td>
<td>Anabolic and survival suppression</td>
<td>Often appears downstream of broader stress and chaperone disruption.</td>
</tr>
<tr>
<td>7</td>
<td>Invasion metastasis and angiogenesis programs</td>
<td>CXCR4 ↓; motility ↓; VEGF signaling ↓; HIF-1α ↔ (context-dependent)</td>
<td>↔</td>
<td>G</td>
<td>Reduced metastatic competence and tumor vascular support</td>
<td>HIF-1-related effects are mixed across sources and models; anti-invasive and anti-angiogenic effects are better supported than a uniform HIF-1α direction.</td>
</tr>
<tr>
<td>8</td>
<td>NRF2 antioxidant response</td>
<td>↑ adaptive defense or overwhelm (context-dependent)</td>
<td>↑ cytoprotective stress response</td>
<td>R/G</td>
<td>Bidirectional redox adaptation</td>
<td>Relevant, but not a clean core anticancer mechanism. NRF2 activation can be protective in normal tissue yet may also buffer tumor oxidative stress in some settings.</td>
</tr>
<tr>
<td>9</td>
<td>Chemosensitization</td>
<td>↑ therapy response</td>
<td>↔ / toxicity risk</td>
<td>G</td>
<td>Overcoming resistance in selected models</td>
<td>Supported especially where NF-κB/STAT3-dependent resistance is prominent; still largely preclinical.</td>
</tr>
<tr>
<td>10</td>
<td>Clinical Translation Constraint</td>
<td>Exposure limited</td>
<td>Toxicity limited</td>
<td>—</td>
<td>Narrow therapeutic window</td>
<td>Poor solubility, poor oral bioavailability, rapid metabolism/disposition, and organ-toxicity risk are major barriers to systemic oncology use.</td>
</tr>
</table>
<p><b>TSF legend:</b><br>
P: 0–30 min (direct redox/protein interactions)<br>
R: 30 min–3 hr (acute stress and signaling shifts)<br>
G: >3 hr (gene regulation and phenotype outcomes)</p>